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1. Introduction
In recent decades, considerable efforts have been made in 
precision cancer therapy, which aims to customize appro-
priate treatment decisions based on individual cases.[1] Though 
advances in DNA profiling and next-generation sequencing 
Cancer heterogeneity is a notorious hallmark of this disease, and it is desir-
able to tailor effective treatments for each individual patient. Drug combina-
tions have been widely accepted in cancer treatment for better therapeutic 
efficacy as compared to a single compound. However, experimental complexity 
and cost grow exponentially with more target compounds under investigation. 
The primary challenge remains to efficiently perform a large-scale drug combi-
nation screening using a small number of patient primary samples for testing. 
Here, a scalable, easy-to-use, high-throughput drug combination screening 
scheme is reported, which has the potential of screening all possible pairwise 
drug combinations for arbitrary number of drugs with multiple logarithmic 
mixing ratios. A “Christmas tree mixer” structure is introduced to generate a 
logarithmic concentration mixing ratio between drug pairs, providing a large 
drug concentration range for screening. A three-layer structure design and 
special inlets arrangement facilitate simple drug loading process. As a proof 
of concept, an 8-drug combination chip is implemented, which is capable of 
screening 172 different treatment conditions over 1032 3D cancer spheroids 
on a single chip. Using both cancer cell lines and patient-derived cancer cells, 
effective drug combination screening is demonstrated for precision medicine.
Precision Medicine
have identified thousands of mutations 
that are critical to cancer progression,[2,3] 
this genotypic method does not always 
pinpoint ideal cancer therapeutics due to 
the limited biological understanding.[4] In 
addition, the presence of non-DNA genetic 
variations, including epigenetic modifica-
tions, lineage-specific changes and tumor 
microenvironment modulations,[5] could 
make it even more complicated to corre-
late cancer cell genetic information with 
clinical consequences.[6,7] These draw-
backs can be addressed by empirical phe-
notypic drug testing,[8,9] in which patient 
cancer cells are exposed to multiple treat-
ments in vitro as a therapeutic guidance 
for individual patients.[10]
As compared to mono-drug treatment, 
drug combination has emerged as treat-
ments for many diseases,[11] especially for 
cancer due to its difficulty in treatment 
and cellular heterogeneity.[12] Although 
many new cancer drugs have been devel-
oped, mono-drug treatments typically fail 
curing cancer[13] due to the existence of alternative pathways 
to compensate the pathway target of drug.[14,15] In order to 
overcome the limitations of mono-drug therapies, drug com-
binations, which aim to inhibit multiple redundant pathways 
of tumor cells,[16] have been widely accepted for better thera-
peutic efficacy.[17] To identify appropriate drug combinations, it 
is desirable to include more compound candidates,[18] yet the 
resulting experimental complexity and cost increases exponen-
tially.[19] For example, investigation of 50 different compounds 
in pairwise combination yields 122550 2C =  different combina-
tions. Furthermore, we assume 7 different concentration ratios 
for each combination, and 6 replicates for each treatment con-
dition, which yields 1225 × 7 × 6 × 10 = 51 450 experiments. 
This is not only costly but also time-consuming for a typical test 
panel of well-plate platforms.
In 2013, The US Food and Drug Administration expressed 
their dedication in developing novel combinatorial therapies, 
highlighting the need for innovative technologies to accelerate 
the discovery of novel drug combinations.[20,21] To achieve high-
throughput drug combination screening, several systems have 
been presented incorporating robotics and automatic han-
dling.[22] However, they are limited by complicated operation 
systems[23] and time-consuming serial processes.[21] Micro-
fluidics emerges as a promising technology for both clinical 
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precision medicine and industrial-scale drug discovery,[24] 
thanks to its capability of handling small samples and highly 
multiplexed operations for high-throughput assays.[25] Previous 
microfluidic high-throughput drug screening platforms intro-
duce a “Christmas tree structure” to generate a linear drug 
concentration gradient, but they are limited to the combina-
tion of two drugs,[26,27] which may not meet the needs for high-
throughput drug screening. In addition, since cells respond 
to different drug concentrations in a nonlinear manner, in 
some cases drug screening experiments require testing dos-
ages ranging several orders of magnitude to calculate the 50% 
inhibition concentration (IC50).[28] The narrow concentration 
range provided by conventional microfluidic linear gradient 
generators severely limits the use of microfluidics in drug 
screening.[29] Previous work using microfluidic generating loga-
rithmic concentration gradient requires complicated valve oper-
ation and interface system, which is not desirable for routine 
drug screening application.[30]
Furthermore, conventional in vitro cancer drug screening 
was mostly performed on 2D well-plates as a simple, fast, 
and cost-effective tool.[31] However, accumulating evidence on 
in vitro cancer studies shows that a large number of cellular 
features and gene expression are skewed in a 2D culture envi-
ronment,[32] which makes it less reliable to make accurate 
clinical decisions. 3D cell culture systems have been widely 
used as better models in mimicking the in vivo tumor micro-
environment,[33] and have become increasingly popular in 
drug screening studies.[34] In this work, we report a scalable, 
easy-to-handle, high-throughput drug combination screening 
scheme, incorporated with custom software for drug efficacy 
readout and data analysis. The presented microfluidic design 
enables screening of all possible pairwise drug combinations 
from arbitrary number of different drugs. As a proof of con-
cept, we demonstrated an 8-drug screening chip with loga-
rithmic concentration gradient, and performed drug combina-
tion screening experiment with multiple cell lines. Combining 
288 2C =  drug combinations, 6 mixing ratios, and 6 replicates, 
plus some single compound control chambers, a total of 
1032 drug efficacy screening experiments can be accomplished 
in a single 8-drug screening chip. Using the presented chip, 
we successfully performed drug combination screening of 
pancreatic cancer patient-derived cell lines, as a demonstration 
for precision medicine applications.
2. Results and Discussion
2.1. Microfluidic Filter Structure for Cell Capture and Sphere 
Formation
The proposed drug combination screening chip consists of 
1032 microtumor culture units, (28 drug combinations × 7 
concentration mixing ratios + 4 culture media controls) × 6 
replicates = 1032. Cells loaded to the chip will be automatically 
distributed to all the culture chambers to form microtumors. To 
facilitate cell capturing and microtumor culturing, each culture 
unit is composed of a center sphere culture chamber, a ring 
chamber surrounding the center sphere culture chamber, and a 
thin gap (5 µm in height, 50 µm in length) connecting the two 
chambers. A total of 20 octagon micropillars (5 µm in height, 
25 µm in side length, and 25 µm in spacing between pillars) are 
sparsely deployed between the polydimethylsiloxane (PDMS) 
thin gap to provide mechanical support and prevent the thin 
gap from collapsing (Figure 1a).
2.2. Microfluidic Tree Structure as Logarithmic Concentration 
Gradient Generator
We presented a “Christmas tree mixer” structure with nonu-
niform channels sizes to achieve a logarithmic mixing ratio 
gradient between two different compounds. The “Christmas 
tree mixer” is composed of five stages of microfluidic meander 
channels, with an incremental number from three to seven in 
each stage (Figure 2a). Solutions containing two different com-
pounds are introduced from the top inlets and flow through 
the microchannel network. The fluid streams are combined in 
each branch channel stage, yielding mixture of distinct compo-
sitions, and splitting to the next stage. Finally, a concentration 
gradient is generated across the last stage of branching chan-
nels.[26] The splitting ratio of the flow at each stage is deter-
mined by the flow resistance. According to Hagen-Poiseuille 
equation, hydraulic resistance of a channel is approximately 
inversely proportional to squared channel width.[35] When all 
the microfluidic meander channels are designed to be of the 
same size (width, height, length), the flow resistance through 
all the branch channels are the same. In this case, a linear con-
centration gradient with an arithmetic progression ratio will be 
established in the last stage.
However, most drug screening experiments require log-scale 
concentration gradient covering a wider concentration range. 
In order to generate nonlinear concentration gradient, channels 
on both left and right sides are designed to be wider than those 
at the center, so that the flow resistance of meander channels on 
the sides are smaller than that of the channels at the center. For 
example, two drug compounds, A and B, are loaded on the two 
sides of the mixer (Figure 2a). Due to a small flow resistance in 
side channels compared to center channels, mostly of the flow 
will be guided side channels, while only a small portion mixed 
with each other at the center meander channels. In this case, 
when the mixture from the previous stage flowing to the next 
stage, a large volume of compound A from the channels on the 
left merged with the small volume of mixture compound A + B 
from the center channel, yielding a mixture containing mostly 
A with a small portion of B. The more drastically different the 
volumes are; the less amount of compound B is contained 
in the final mixture, the larger concentration ratio of com-
pound A to compound B is. In this manner, we can generate a 
logarithmic concentration gradient (Figure 2b). (Quantitative 
analysis is described in the Supporting Information).
Another critical design of this chip is that meander channels 
at the last stage (i.e., fifth stage) of mixer array have the same 
dimension, instead of following the previously described rule 
of “side channels wider than center channels.” This last stage 
meander channels are used as a “buffering layer” between the 
upstream “Christmas tree mixer” and downstream sphere cul-
ture chambers (Figure 2c). The rationale behind this last stage 
meander channel design is that the sphere culture chambers 
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Figure 1. Spheroid formation in culture chambers. a) Laser confocal microscopy image of a unit chamber. Cells were captured at 5 µm gap mechanically 
supported by micropillars. b) Spheroid culture chamber cross-section profile measured by Olympus OLS 4000 LEXT with a concave bottom of 16 µm 
in depth. c) Microscopy image of SUM159 breast tumor spheroids forming in sphere culture chambers. (Scale bar = 200 µm) d) Size distribution of 
spheroids formed in the culture chambers.
Figure 2. COMSOL simulation results for logarithmic “Christmas tree mixer” structure a) Concentration simulation of “Christmas tree mixer” using 
COMSOL. b) Measurement of the concentration of both drug A and drug B at the final stage of the mixer. c) Velocity simulation of “Christmas tree 
mixer” using COMSOL. d) Flow rate measurement of the channels in 4th stage and 5th stage (last stage), validating that the last stage can be a “buff-
ering layer” to balance the flow rates among between branches.
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connected to the downstream also contributes to the equivalent 
resistance of the last stage of the “Christmas tree mixer.” Even 
if the channel dimension of the last stage is carefully designed, 
because of the contributions of the hydraulic resistance from 
the downstream microfluidic structure, the equivalent resist-
ance seen from the previous stage will be affected. On the other 
hand, the “Christmas tree mixer” also have an influence on 
the flow resistance of cell capture structures. When cells are 
loaded from cell inlets to cell culture chambers, the imbalanced 
channel design of “Christmas tree mixer” will also affect the 
cell loading uniformity, resulting in more cells loaded to cham-
bers that are connected to side channels due to a lower flow 
resistance. Channels of the same dimension at the last stage of 
“Christmas tree mixer” help balance the cell loading and form 
tumor spheres of uniform size among all branches (Figure S2, 
Supporting Information).
We demonstrate the COMSOL simulation results of the 
presented mixer structure (Figure 2a), in which the channel 
dimension is designed to be symmetric. As described above, 
the channels at the last stage are the same in dimension 
(90 µm in width). To achieve the proper range of mixing ratios, 
the center channels are designed to be 60 µm in width, the 
channels on both sides are 120 µm in width, while the chan-
nels in between are 90 µm in width. As a result, seven con-
centration ratios between drug A and drug B are achieved at 
a logarithmic gradient, ranging in 1:106, 1:100, 1:10, 1:1, 10:1, 
100:1, and 106:1 (Figure 2b), which is desirably wide for drug 
screening platforms.
2.3. Mixer Array and Drug Inlets “Sudoku Puzzle”
By deploying the “Christmas tree mixer” structures, we could 
generate a concentration gradient between two drugs. However, 
if all the 288 2C =  combinations of 8 drugs need to be screened 
using “Christmas tree mixer” side by side, at least 28 × 2 = 56 
drug inlets should be deployed, which requires a very com-
plicated microfluidic interface tubing system. To address this 
issue, adjacent Christmas tree mixers are designed to share 
a common drug inlet. However, this design requires special 
arrangement of the inlet array to guarantee the adjacent drug 
pairs covers all the possible combinations. For example, if we 
have 4 drugs, we could arrange the drug inlets as shown in 
Table 1.
In which, number 1–4 stand for 4 different drugs, and there 
is a “Christmas tree mixer” between each number pairs to gen-
erate concentration gradient. In this case, all the possible pair-
wise combinations, 1–2, 2–3, 3–4, 1–3, 2–4, and 1–4 are covered. 
However, the arrangement problem becomes much more com-
plicated when the drug number becomes larger, for example, 
the computational complexity could reach 1026 possible permu-
tations when the drug number comes to 16. To make it possible 
for scaling-up, a general solution to the inlets arrangement is 
require so that the same design strategy could be applied to any 
arbitrary number of drugs. Although there are many possible 
solutions that could fulfill the requirements, we find a general 
solution for all even number of drugs. To make it convenient to 
explain, we rephrase the inlets arrangement problem to the fol-
lowing “Sudoku puzzle” problem:
Let N be any even number, use number 1–N to fill in a table 
with N columns and N/2 rows. If we define the combination of 
horizontally adjacent numbers as a “pair,” also define “1, 2” and 
“2, 1” are the same pair. We will have N × (N − 1)/2 pairs in the 
table. Try to fill in table, such that
a) Each row contains N nonrepeating numbers from 1 to N.
b) All the N × (N − 1)/2 pairs are nonrepeating, as well as cover-
ing all the possible combinations.
Since all the requirements are made on adjacency relation-
ship, we find it very convenient to introduce an “adjacency 
relationship matrix” to keep record of the existing adjacent 
number. By following some rules in filling “adjacency relation-
ship matrix” and putting certain numbers in the corresponding 
entries in “Sudoku puzzle,” we are able to solve the “Sudoku 
puzzle” for any arbitrary even number (Supporting Informa-
tion). As a demonstration, we showed the matrix for 16 drugs 
(Table 2).
In this work, due to the limitation of wafer area and avail-
ability of chemo-drugs, we only conduct experiment on devices 
for 4 and 8 drugs. However, we would like to show the poten-
tial of scaling up the design to allow combinatorial screening 
of arbitrary even number of drugs. As a proof of concept, we 
demonstrate a “sudoku puzzle” for 50 drugs, guaranteeing all 
the “horizontal adjacent pairs” are nonrepeating, while covering 
Small 2018, 14, 1703617
Table 1. Example drug inlets layout for 4 drugs. Number 1,2,3,4 stands 
for 4 different drugs.
1 2 3 4
2 4 1 3
Table 2. Example drug inlets layout for 16 drugs. Number 1–16 stands for 16 different drugs.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
2 4 1 6 3 8 5 10 7 12 9 14 11 16 13 15
3 1 5 2 7 4 9 6 11 8 13 10 15 12 16 14
4 6 2 8 1 10 3 12 5 14 7 16 9 15 11 13
5 3 7 1 9 2 11 4 13 6 15 8 16 10 14 12
6 8 4 10 2 12 1 14 3 16 5 15 7 13 9 11
7 5 9 3 11 1 13 2 15 4 16 6 14 8 12 10
8 10 6 12 4 14 2 16 1 15 3 13 5 11 7 9
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all the possible pairwise combinations (Figure S5, Supporting 
Information).
2.4. Multiple PDMS Layers for Drug Mixing and Routing
As described in previous drug inlets array section, even if 
the inlet number could be reduced by sharing common drug 
inlets, there are still many inlets for each drug. For example, 
for a 16-drug combination screening chip, it is labor-inten-
sive to load all the 16 drugs into 162/2 = 128 drug reservoirs, 
especially when there are many chips to operate. In order to 
further minimize the pipetting/tubing number, we present 
a three-layer chip design inspired by multilayer circuit board 
design. The three PDMS layers are routing layer, mixing layer, 
and lid layer from bottom to top (Figure 3a). In the mixing 
layer, different drug compounds are combined using previ-
ously mentioned “Christmas tree mixers” that are patterned on 
it, together with sphere culture chambers (Figure 3b). In the 
routing layer, a total of N (N = number of drugs to be screened) 
microfluidic channels are implemented to connect multiple 
drug reservoirs for the same drug. Through these routing chan-
nels with extremely large cross-section area, thus negligible 
flow resistance compared to microchannels in the mixing layer, 
each drug compound can be automatically dispensed to all the 
drug inlets within seconds. The layout of the routing channels 
could be generated and optimized automatically using PADS 
Autorouter, a circuit board design software (Figure 3c). Since 
the flow resistance of the routing channels is extremely small 
(around 4 orders of magnitude) compared to that of the mixing 
layer, the drug solution will fill all the drug reservoirs in sec-
onds when one of the certain drug is loaded to any of the drug 
reservoirs. The lid layer PDMS covers the mixing layer to form 
an enclosed microfluidic system. The mixing PDMS layer 
was flipped to face upward before bonding to lid layer, so that 
cells could be captured at the 5 µm thin gap in each individual 
chamber.
2.5. Validation of Logarithmic Concentration Gradient On-Chip
In order to test drug solution mixing on-chip, both fabricated 
linear concentration gradient device and logarithmic concen-
tration gradient device were loaded with fluorescent dyes. 
The fluorescent intensity profile could be used to represent 
the concentration of different drugs. Phosphate-buffered 
saline (PBS no fluorescence) and three fluorescence dyes 
with different excitation wavelength were used: Tetrameth-
ylrhodamine (TRITC, red), Fluorescein (green), and DAPI 
(blue). After overlaying all the fluorescent images from each 
channel, we observed a rainbow-like color gradient formed 
in linear concentration gradient device (Figure 4a). By meas-
uring the fluorescence intensity of all dyes, we verified each 
of the pairwise compound was mixed in six concentration 
ratios of 0%:100%, 20%:80%, 40%:60%, 60%:40%, 80%:20%, 
and 100%:0%, which is accordant with simulation results 
(Figure 4c). For logarithmic gradient generator, due to the 
tradeoff between the dynamic range and detection resolution 
Small 2018, 14, 1703617
Figure 3. Schematics of multiplexed 8-drug combination screening chip. a) Separate views of three PDMS layers. 32 holes are punched through all the 
three PDMS layers for drug inlets using 6 mm biopsy punch, connecting the mixing and routing layers. b) Top view of the mixing layer: 32 inlets are 
allocated to 8 drugs, with a group of 4 connecting to each other with the same number in the routing layer. Before drug treatment, cells were loaded 
to the inlets and automatically deployed to 1032 culture chambers driven by gravity flow. Cell inlets are also used for drug outlet during drug treatment 
process. c) Top view of the routing layer, same number on different rows are connected in routing layer.
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of camera, different exposure times were needed to valida-
tion high concentration region and low concentration region, 
respectively. One image was taken with short exposure time 
(30 ms) to achieve larger detection range and avoid fluo-
rescence saturation, so that the concentration relationship 
between 10%, 50%, and 90% could be verified (Figure 4b); 
While the other image is taken using long exposure time 
(300 ms), enabling the measurement of fluorescence intensity 
difference between 0%, 1% and 10% (Figure S6, Supporting 
Information). Thus, combining the measurement in these 
two images, it was validated that the logarithmic mixing ratio 
in fabricated device matches well with COMSOL simulation 
results (Figure 4d).
2.6. Cancer Cell Loading and Sphere Formation
For cell loading balance considerations, two cell inlets are 
used on both left side and right side. In the loading pro-
cess, 500 µL cell suspension is loaded to both cell loading 
inlets, while the 32 drug inlets are left empty, which are used 
as outlets. Driven by the pressure difference between cell 
loading inlets and drug loading inlets, cells are distributed to 
1032 sphere culture chambers, and captured at the 5 µm thin 
gap in each individual chamber. The chamber bottom was 
designed to be curved (Figure 1b), so that cells finally aggre-
gate at the rounded bottom in central octagonal chamber, 
which is coated with Pluronic-108. After culturing cells for 
Small 2018, 14, 1703617
Figure 4. Generation of linear and logarithmic concentration gradient validated by fluorescent dye a) Linear gradient generation using PBS, Fluorescein 
(green), tetramethylrhodamine (red), and DAPI (blue), from left to right. The final image was created by overlapping images of the brightfield, FITC, 
TRITC, and DAPI channels. b) Logarithmic gradient generation using tetramethylrhodamine (red), DAPI (blue), PBS, and Fluorescein (green), from left 
to right. The final image was created by overlapping images of the brightfield, FITC, TRITC, and DAPI channel. c) Comparison of fluorescent intensity 
between linear gradient generation experiment (solid lines) and simulation results (dashed lines). d) Fluorescent intensity measurement of logarithmic 
gradient generation experiment (solid lines), which correlates well with simulation (dashed lines). (Scale bar = 500 µm).
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1 day, cells form spheroids of uniform size (Figure 1c). By 
regulating chamber dimensions, we are able to control the 
equivalent flow resistance of the cell culture gap. The larger 
the chamber dimension is, the smaller the flow resistance is. 
As a result, the more cells could be captured at the cell cap-
ture gap and the larger the spheroids could be finally formed. 
As a demonstration, we showed that two different sizes of 
spheres could be achieved (large sphere: 238 ± 16 µm in 
diameter, small spheres: 124 ± 11 µm in diameter), with 
two different chamber dimension designs (large chamber: 
440 µm in diagonal, small chamber: 240 µm in diagonal), 
respectively (Figure 1d).
2.7. Drug Combination Screening on Breast and Pancreatic 
Cancer Cell Lines
To demonstrate the efficacy of high-throughput drug combina-
tion screening, we conducted a screening experiment with pan-
creatic cancer cell line, MIA PaCa-2, using a fabricated 8-drug 
logarithmic concentration gradient chip. All the pairwise com-
binations of seven chemo-drugs (Cisplatin, Docetaxel, Doxo-
rubicin, Gemcitabine, Irinotecan, Oxaliplatin, Fluorouracil) 
together with culture media positive control were screened in a 
single-chip (Figure 5). As a result, we identified a few drug com-
binations with high synergistic indexes, which were highlighted 
Small 2018, 14, 1703617
Figure 5. Drug combination screening results of control (culture media) and 7 drugs (Cisplatin, Docetaxel, Doxorubicin, Gemcitabine, Irinotecan, 
Oxaliplatin, 5-FU) using pancreatic cancer cell line MIA PaCa-2. Each subplot in the lower triangular table illustrates the cell death rate under the 
combination of drugs at each corresponding row and column. Each bar with different colors represent different concentration mixing ratio of certain 
drug combination. “Maximum Synergistic Index” (MSI) is denoted at upper triangle table, which is defined by the largest synergistic index among 
all the screened mixing ratio between the pair of drugs. Synergistic drug combination pairs with high MSI (>1.4) are highlighted in red, while those 
nonsynergistic ones with low MSI (<1.1) are highlighted in blue.
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in red. For example, the combination of docetaxel + irinotecan, 
doxorubicin + 5-FU, docetaxel + oxaliplatin, and gemcitabine + 
Irinotecan showed synergistic indexes higher than 1.4, which 
have been proven to be more effective than single drugs in 
previous clinical and research literatures.[36–39] While the non-
synergistic drug combinations, highlighted in blue in the table, 
such as cisplatin + oxaliplatin and gemcitabine + 5-FU[40] may 
result from their similar mechanism of action. Both cisplatin 
and oxaliplatin are DNA alkylating agents forming platinated 
intra-strand and inter-strand cross-link, interfering with DNA 
replication.[41] While gemcitabine and 5-FU are both belongs 
to nucleoside analog family of medication, which induces cell 
apoptosis by inhibiting the synthesis of new DNA.[42] We fur-
ther demonstrated the general usage for the presented chip for 
other types of cancer cell lines using SUM159 and MCF7, on 
a fabricated 4-drug screening chip with linear concentration 
gradient mixer (Figure S3, Supporting Information). We also 
showed reliable drug combination screening result among 4 
fabricated 8-drug screening chips using SUM159 breast cancer 
cells, with negligible drug efficacy variations among different 
chips (Figure S4, Supporting Information).
2.8. Drug Combination Screening on Pancreatic Cancer Patient-
Derived Xenograft (PDX) Cell Line
PDX models have been believed as an in vitro cancer model 
that is more physiologically relevant and readily applicable 
to the clinics, due to its preservation of the inter-tumor and 
intra-tumor heterogeneity, as well as the phenotypic and 
molecular characteristics of the original cancer.[43] Thus, 
we further tested pancreatic cancer PDX cell lines to dem-
onstrate the potential of presented chip for precision medi-
cine. Combining the drug combination screening results 
of three PDX cell line samples, UM5, UM16, and UM53 
(Figures S7–S9, Supporting Information), we established gen-
eral drug responses of pancreatic cancer to a panel of combi-
nation treatments (Figure 6a). Among all drug combinations, 
a few of them with high average inhibition rate, such as 
fluorouracil + oxaliplatin, gemcitabine + oxaliplatin, and doc-
etaxel + oxaliplatin, are identified as generally effective drug 
combinations for pancreatic cancer treatment. In fact, both 
fluorouracil + oxaliplatin and gemcitabine + oxaliplatin have 
been approved by US Food and Drug Administration (FDA) 
for pancreatic cancer combinatorial treatment.[44] In addition, 
we also pinpointed the unique drug responses of each PDX 
sample. For UM16, none of the well-accepted drug combina-
tion was effective in inhibiting cell growth (Figure 6b). The 
nonconventional combination of gemcitabine and docetaxel, 
however, achieved a good drug efficacy. UM5 showed resistant 
to most of the drug compound except for the combination of 
10% gemcitabine and 90% Oxaliplatin (Figure 6c). The het-
erogeneous drug response among different patient samples 
confirmed the importance of customizing personalized chem-
otherapy for each individual. The successful combinatorial 
drug screening experiments using PDX cell lines suggest the 
potential of the presented platform in discovering new combi-
nation and precision medicine.
Small 2018, 14, 1703617
Figure 6. Drug combination screening results of control (culture media) and 7 drugs (Cisplatin, Docetaxel, Doxorubicin, Gemcitabine, Irinotecan, 
Oxaliplatin, 5-FU) using pancreatic cancer PDX cells. 172 different pairwise drug combinations with different mixing ratios are listed in X-axis. 
a) Average drug response of all PDX cells for 172 different drug treatment conditions. b) UM16 relative drug responses compared to the average drug 
response of all PDX cells. c) UM5 relative drug responses compared to the average drug response of all PDX cells. d) UM53 relative drug responses 
compared to the average drug response of all PDX cells.
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3. Conclusion
We reported a high-throughput, easy-handling, multiplex 
drug-combination screening platform scheme. By innovatively 
using three-layer PDMS structure, drug inlets sharing scheme, 
and specially arranged drug inlets array, we successfully dem-
onstrated the feasibility of scaling up combinatorial drug 
screening for larger number of drugs. In addition, we presented 
a logarithmic concentration gradient generator, which provides 
a wider dynamic concentration range as compared to linear 
gradient generator. Furthermore, we adopted 3D tumor sphe-
roids models for drug screening to better mimic in vivo tumor 
microenvironment. The design of spheroid culture chamber 
with 5 µm cell capture gap, micropillar array, and rounded 
bottom structure guaranteed the formation of uniform sphe-
roids of 238 ± 16 µm in size. As a demonstration of the design 
scheme, we fabricated an 8-drug combination screening chip, 
which generates 8C2 = 28 pairwise drug combinations, with 7 
mixing ratios between each pair of drugs, yielding 172 different 
treatment conditions. Combining 6 replicates for each treat-
ment condition, 1032 drug efficacy screening experiments can 
be accomplished in a single 8-drug screening chip. The drug 
screening experiment using pancreatic cancer cell line, MIA-
PaCa-2, identified the synergistic effects between docetaxel + 
Irinotecan, doxorubicin + 5-FU, docetaxel + oxaliplatin, and 
gemcitabine + Irinotecan, which match well with the clinical 
trial results reported in literature. We further verified the appli-
cation of the fabricated chip in precision medicine using PDX 
cell lines, which better mimic the drug response of patients. We 
pinpointed the most synergistic drug combinations for each 
patient based on our screening results. The preliminary results 
verified the efficacy and synergistic effect of high-throughput 
drug combination screening. The presented design approach is 
easily scalable to incorporate a large number of drugs for large-
scale drug screening.
4. Experimental Section
Device Fabrication: The drug combination screening chip consisted of 
three PDMS layers: routing layer, mixing layer, and lid layer, from bottom 
to top (Figure 3a). The three PDMS layers were fabricated separately 
using standard soft lithography with silicon wafers as the mold. Four 
chrome-coated glass masks were used in fabricating the SU8 master 
molds. One of the four masks were used to create channels in routing 
layer (800 µm in width, 300 µm in height), while the other three masks 
were used for mixing layer: the first mask was for thin cell capture gap 
(5 µm in height) with micropillars supporting structure; and the second 
mask defined patterns for the main microfluidic channels and sphere 
culture chambers (100 µm in height). The third mask was a dark-field 
mask with clear patterns of the central sphere culture chamber. The 
purpose of the third mask was to generate a rounded chamber bottom 
profile for better cell aggregation and sphere formation. SU8-2010 
(MicroChem, NC9047158) was spun at 1000 rpm for 30 s above the 
first two SU8 layers. Since the average SU8-2010 spreading thickness 
at 1000 rpm, which is around 20 µm, is thinner than the second SU8 
layer (100 µm), instead of covering all the surface, the newly spun 
SU8-2010 will form a rounded profile above the octagon sphere culture 
chamber patterns due to surface tension. The curvature is dependent 
on the viscosity of the photoresist, surface properties of the patterned 
surface, as well as the pattern dimensions. Using this protocol, a curved 
surface with center thickness of 16 µm (Figure 1b) was being able to be 
created. PDMS (Dow Corning Sylgard 184, DC4019862) was cured on 
SU8 master at 100 °C for 1 day and then peeled off from silicon mold; 
the three PDMS layers were treated with O2 plasma treatment at 100W 
for 60 s, followed by alignment and bonding together. 6 mm diameter 
holes were punched through the three PDMS layers as drug reservoirs, 
and 10 mm diameter holes as cell loading inlets. The fabricated chip was 
exposed to UV radiation to ensure sterilized conditions before use.
Cell Culture: Pancreatic cancer cell line and patient-derived cells were 
cultured both in bulk and in drug combination screening chip. Mia 
PACA-2, UM5, UM16, and UM53 cells were obtained from Dr. Simeone’s 
Lab (University of Michigan, MI, USA). Pancreatic cells were cultured in 
RPMI (Gibco 11875) with 10% FBS (Gibco 10082) and 1% penicillin/
streptomycin (Gibco 15140). All the cells were cultured in polystyrene 
culture dishes at 37 °C and 5% CO2, and passaged when cells reached 
over 80% confluency in the dish.
Cancer Drug Inventory: Cisplatin, cis-diamminedichloroplatinum (CAS 
15663-27-1) was obtained from Cayman Chemical (Cat. No. 13119). 
Doxorubicin hydrochloride (CAS 25316-40-9) was obtained from Cayman 
Chemical (Cat. No. 15007). Gemcitabine (CAS 95058-81-4) was obtained 
from Accord (NDC No. 16729-092-03). Irinotecan hydrochloride (CAS 
100286-90-6) was obtained from Cayman Chemical (Cat. No. 14180). 
Oxaliplatin (CAS 61825-94-3) was obtained from Cayman Chemical (Cat. 
No. 13106). Docetaxel (CAS 114977-28-5) was obtained from Cayman 
Chemical (Cat. No. 11637). Fluorouracil (CAS 51-21-8) was obtained 
from Sigma-Aldrich (Cat. No. F6627).
PDX Protocol: Patient-derived cells were obtained from PDX model 
in Dr. Simeone’s Lab, following the protocol as in previous literature.[45] 
Samples of human pancreatic adenocarcinomas were obtained 
within 30 min following surgical resection according to Institutional 
Review Board–approved guidelines. Tumors were suspended in and 
mechanically dissociated using scissors and then minced with a sterile 
scalpel blade over ice to yield 2  × 2 mm pieces. The tumor pieces were 
washed with serum-free PBS before implantation. Eight-week-old male 
non-obese diabetic/severe combined immune deficiency (NOD/SCID) 
mice were anesthetized using an i.p. injection of 100 mg kg−1 ketamine 
and 5 mg kg−1 xylazine. A 5 mm incision was then made in the skin 
overlying the midabdomen, and three pieces of tumor were implanted 
s.c. The skin incision was closed with absorbable suture. The mice were 
monitored weekly for tumor growth for 16 weeks.
Before digestion with collagenase, xenograft tumors or primary 
human tumors were cut up into small pieces with scissors and then 
minced completely using sterile scalpel blades. To obtain single-cell 
suspensions, the resultant minced tumor pieces were mixed with 
ultrapure collagenase IV (Worthington Biochemicals, Freehold, NJ) in 
medium 199 (200 units of collagenase per mL) and allowed to incubate 
at 37 °C for 2.5 to 3 h for enzymatic dissociation. The specimens were 
further mechanically dissociated every 15 to 20 min by pipetting with a 
10 mL pipette. At the end of the incubation, cells were filtered through 
a 40 Am nylon mesh and washed with Hank’s balanced salt solution 
(HBSS)/20% fetal bovine serum (FBS) and then washed twice with 
HBSS.
Dissociated cells were counted and transferred to a 5 mL tube, 
washed twice with HBSS containing 2% heat-inactivated FBS, and 
resuspended in HBSS with 2% FBS at concentration of 106 per 100 µL. 
Sandoglobin solution (1 mg mL−1) was then added to the sample at a 
dilution of 1:20 and the sample was incubated on ice for 20 min. The 
sample was then washed twice with HBSS/2% FBS and resuspended 
in HBSS/2% FBS. Antibodies were added and incubated for 20 min 
on ice, and the sample was washed twice with HBSS/2% FBS. When 
needed, a secondary antibody was added by resuspending the cells in 
HBSS/2%FBS followed by a 20-min incubation. After another washing, 
cells were resuspended in HBSS/2% FBS containing 4’,6-diamidino-
2-phenylindole (DAPI; 1 Ag mL−1 final concentration). The antibodies 
used were anti-CD44 allophycocyanin, anti-CD24 (phycoerythrin), and 
anti-H2K (PharMingen, Franklin Lakes, NJ) as well as anti–ESA-FITC 
(Biomeda, Foster City, CA), each at a dilution of 1:40. In all experiments 
using human xenograft tissue, infiltrating mouse cells were eliminated 
by discarding H2K (mouse histocompatibility class I) cells during flow 
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cytometry. Dead cells were eliminated by using the viability dye DAPI. 
Flow cytometry was done using a FACSAria (BD Immunocytometry 
Systems, Franklin Lakes, NJ). Side scatter and forward scatter profiles 
were used to eliminate cell doublets. Cells were routinely sorted twice, 
and the cells were reanalyzed for purity, which typically was >97%.
Sorted cells were washed with serum-free HBSS after flow cytometry 
and suspended in serum free-RPMI/Matrigel mixture (1:1 volume) 
followed by injection s.c. into the right and left midabdominal area using 
a 23-gauge needle. In separate experiments, mice were anesthetized 
with an i.p. injection of 100 mg kg−1 ketamine and 5 mg kg−1 xylazine, 
a median laparotomy was done, and either 1000 or 5000 sorted cells. 
Animals underwent autopsy at 28 days after cell implantation and tumor 
growth was accessed. Tissues were fixed in formaldehyde and examined 
histologically.
Cell Loading: To facilitate 3D cell culture, the device surface was 
coated with a well-characterized, commercially available, PEO-
terminated triblock polymer, Pluronic F108, which has been shown to 
be nonimmunogenic, nontoxic, and FDA approved for a wide usage in 
medical applications[46] (Figure S1, Supporting Information). 5% (w/w) 
Pluronic F-108 (CAS 9003-11-6, BASF) in DI water was loaded to the 
device 12 h before cell loading to create nonadherent surface.[47] Before 
cell loading, devices were washed by PBS(Invitrogen, ILT10010023). 
For cell loading, 500 mL cell suspension was added to each of the cell 
loading inlets and was driven to all the cell culture chambers by gravity 
flow. After cell loading, cancer cells were allowed to aggregate to form 
spheroids and grow for 48 h in each sphere culture chambers after 
loaded to the chip. RPMI (Gibco 11875) with 10% FBS (Gibco 10082) 
and 1% penicillin/streptomycin (Gibco 15140) was used as culture 
media to help cancer cells to form tight spheroid.
Drug Screening Protocol and Drug Efficacy Readout: After culturing for 
48 h, culture media were taken out from all the inlets. All the drugs were 
loaded to the corresponding inlets and replaced with new drug solution 
every 12 h before the hydraulic pressure between inlets and outlets fails 
to maintain the flow rate and mixing ratio. All the drugs were dissolved 
to targeted concentration in RPMI (Gibco 10082) serum free media. 
After 72 h treated with drug, the spheroid was stained with using Live/
Dead Viability/Cytotoxicity Kit for mammalian cells (Life technologies, 
L-3224), in which live cells were stained with green fluorescence and 
dead cells with red fluorescence, and were put in an incubator (37 °C, 
5% CO2) for 1 h, followed by fluorescence microscopy imaging. The 
inhibition rate was calculated using the fluorescent intensity ratio of 
live cells to dead cells. A custom program was developed to analyze 
the inhibition rate and drug efficacy in a high-throughput manner 
(Figure S4b, Supporting Information).
Synergy Effect Analysis: To quantify the synergistic effect of various 
drug combinations, “Maximum Synergy Index” (MSI) was calculated 
inspired by loewe additivity.[48] Based on dose equivalence principle, that 
for a given effect, dose a of drug A is equivalent to dose ba of drug B, 
and reciprocally. In addition, dose ba can be added to any other dose b of 
drug B to give the additive effect of the combination. The additive effect 
of drugs A and B can be expressed as[49]
( ) ( )( )+ = + = +Effect A Ba b E a a E b bb a  (1)
To quantify the combination synergistic index, the linear interpolation 
value of each combination with different mixing ratio was first calculated 
based on single drug effect. For example, drug A with dose a yields 
Ia% inhibition rate, while drug B with dose b yields Ib% inhibition 
rate. The combination of drug A and drug B with the mixing ratio of 
1:1 should yields Iab = (Ia% + Ib%)/2 inhibition rate. The “synergy index” 
of drug A and drug B with certain mixing ratio is defined as dividing the 
experimental inhibition rate Iab,exp by theoretical inhibition rate Iab,theory. 
The largest synergistic index among all the screened mixing ratio 
between drug A and drug B, which has the best chance of achieving the 
best therapeutic result, is defined as the MSI of the drug combination 
between A and B. A MSI greater than 1 indicates a synergistic drug 
combination, since the maximum inhibition rate of the drug combination 
is higher than the linear interpolation of individual drugs.
Image Acquisition: The microfluidic chips were imaged using an 
inverted microscope (Nikon). The bright-field and fluorescent images 
were taken with a 10× objectives and a charge-coupled device camera 
(Coolsnap HQ2, Photometrics). FITC and TRITC filter sets were used 
for the fluorescent imaging. The microfluidic cell chamber array was 
scanned with a motorized stage (ProScan II, Prior Scientific). Before 
each scanning, the stage was leveled to ensure the image remained 
in the focus throughout the whole imaging area. To ensure optimized 
image quality, autofocusing was done after imaging every 4 frames. After 
scanning, the Nikon NIS-Elements Basic Research software module 
was used to stitch individual images into a large image for analysis. 
The fluorescent intensity of each spheroid was quantified using Nikon 
Research Basics software. In order to cancel the interference from 
background noise and substrate absorption, background fluorescent 
intensity was subtracted from the signal.
COMSOL Simulation: The COMSOL simulation in this work used 
“laminar flow” model for fluid dynamics. Boundary conditions were 
set as follows: inlet pressure = 100 Pa, outlet pressure = 0 Pa, diffusion 
coefficient = 2 × 10−9 s−1, which equals to the diffusion coefficient 
of cisplatin dissolved in liquid solvent.[50] In addition, “3D transport 
of diluted species” was applied to simulate the mixing between two 
chemical compounds, in which the model parameters were set as 
follow: T = 293.15 K, fluid density = 1000  m−3, dynamic viscosity = 
0.00103 Pa·s The concentration of the compound loaded to two inlets 
are set as: inflow 1 = 0 mmol m−3, inflow 2 = 1 mmol m−3. Normal 
physics-controlled mesh was used.
Data Analysis and Processing: Spheroids smaller than 30 µm in 
diameter were not included for analysis. Statistical analyses and synergy 
index table plot were performed using R (version 3.3.2). Two-tailed, 
unpaired Student’s t-tests were used for all comparisons and significance 
level of p < 0.05 was used to consider statistical significance. * refers to 
p < 0.05, ** refers to p < 0.01, and *** refers to p < 0.001. Results are 
presented as mean ± SD.
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